Clinical Trial Update: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm [Phase 2]

View source ↗

Summary

Phase 2 evaluation of CPX-351 monotherapy in acute myeloid leukemia secondary to myeloproliferative neoplasm has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Acute Myeloid Leukemia, Myeloproliferative Syndrome | Phase 2 | Status: COMPLETED